Clinical Study

Pilot Study To Assess The Efficacy & Safety Of H.P. Acthar Gel In Subjects With Relapsing-Remitting Multiple Sclerosis

Posted Date: Aug 27, 2019

  • Investigator: Lawrence Goldstick
  • Specialties: Multiple Sclerosis, Neurology
  • Type of Study: Drug

This is a multicenter, multiple dose study to estimate the response rate, and examine the safety of H.P. Acthar Gel (Acthar) in subjects with RRMS who have not responded to high dose steroids.


Subjects With Rrms Who Have Experienced A Relapse And Who Will Receive 3 To 5 (Given Over A Period Of Up To 7 Days) Days Of Treatment With High Dose Steroids (Oral Or Iv) Within 28 Days Of The Onset Of Relapse Symptoms Are Candidates For The Current Study.


Relapsing-Remitting Multiple Sclerosis, Rrms, Ms

For More Information:

Sarah Hiti

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.